LeMaitre Vascular (NASDAQ:LMAT) Releases FY 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 2.480-2.530 for the period, compared to the consensus EPS estimate of 2.280. The company issued revenue guidance of $247.0 million-$249.0 million, compared to the consensus revenue estimate of $250.7 million. LeMaitre Vascular also updated its Q4 2025 guidance to 0.640-0.690 EPS.

LeMaitre Vascular Stock Up 1.4%

LMAT traded up $1.22 during trading on Friday, reaching $86.82. The company had a trading volume of 275,971 shares, compared to its average volume of 182,389. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58. The business’s fifty day moving average price is $89.58 and its 200 day moving average price is $87.01. The company has a market cap of $1.97 billion, a P/E ratio of 42.15, a PEG ratio of 2.29 and a beta of 0.77.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. The business had revenue of $61.05 million for the quarter, compared to analyst estimates of $62.18 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period last year, the business posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. Equities analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 4th. Investors of record on Thursday, November 20th will be issued a dividend of $0.20 per share. The ex-dividend date is Thursday, November 20th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.48%.

Analysts Set New Price Targets

LMAT has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Wednesday, October 8th. Barrington Research reissued an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Cantor Fitzgerald increased their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Roth Capital reiterated a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a research note on Wednesday. Finally, Wells Fargo & Company reduced their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a research note on Friday. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $100.20.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director John A. Roush sold 6,561 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the sale, the director owned 2,916 shares in the company, valued at $269,875.80. This represents a 69.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David B. Roberts sold 10,815 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director directly owned 17,976 shares of the company’s stock, valued at approximately $1,660,802.64. The trade was a 37.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently modified their holdings of the stock. Public Sector Pension Investment Board raised its holdings in LeMaitre Vascular by 8.0% in the 2nd quarter. Public Sector Pension Investment Board now owns 70,119 shares of the medical instruments supplier’s stock valued at $5,823,000 after acquiring an additional 5,190 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of LeMaitre Vascular by 398.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,736 shares of the medical instruments supplier’s stock worth $144,000 after purchasing an additional 1,388 shares in the last quarter. Captrust Financial Advisors increased its position in shares of LeMaitre Vascular by 149.4% in the second quarter. Captrust Financial Advisors now owns 9,446 shares of the medical instruments supplier’s stock worth $784,000 after purchasing an additional 5,659 shares during the period. Scott Marsh Financial LLC acquired a new position in LeMaitre Vascular in the second quarter valued at about $581,000. Finally, Lazard Asset Management LLC lifted its position in LeMaitre Vascular by 14.7% during the second quarter. Lazard Asset Management LLC now owns 45,762 shares of the medical instruments supplier’s stock worth $3,800,000 after purchasing an additional 5,849 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.